Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Updated results of axitinib and nivolumab in previously treated mRCC

Elizabeth Plimack • 15 Feb 2025
GU Cancers 2025
Genitourinary Cancer Kidney Cancer Antibodies Axitinib Checkpoint Inhibitors Nivolumab

Elizabeth Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, gives an overview of results from a Phase I/II study (NCT03172754) of axitinib with nivolumab in patients with pre-treated metastatic renal cell carcinoma (mRCC). The combination achieved a notable disease control rate and encouraging overall survival, with some patients remaining progression-free after stopping therapy at two years. Adverse events were consistent with known profiles. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elizabeth Plimack

RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
1:33
RETAIN-2: risk enabled therapy after neoadjuvant chemo-IO in MIBC
Elizabeth Plimack • 15 Feb 2025
CheckMate 274: additional survival outcomes of adjuvant nivolumab in MIBC
1:02
CheckMate 274: additional survival outcomes of adjuvant nivolumab in MIBC
Elizabeth Plimack • 15 Feb 2025
NIAGARA: impact of pCR on outcomes of durvalumab with NAC in MIBC
0:35
NIAGARA: impact of pCR on outcomes of durvalumab with NAC in MIBC
Elizabeth Plimack • 15 Feb 2025
DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer
0:52
DAD trial: combining sacituzumab govitecan and EV for the treatment of bladder cancer
Elizabeth Plimack • 22 Oct 2023

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals